Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has enticing clinical potential that has caught the eyes of more than one bull who have sounded off on this biotech firm's meaningful potential. One enthusiastic voice comes from H.C. Wainwright analyst Ed Arce who sees a lot to look forward to down the line with Aurinia's not-so-secret weapon: voclosporin.
More recent articles about Aurinia:
- Aurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech Index
- Aurinia Has Canaccord Captivated with Voclosporin Prospects
- Analyst Neil Maruoka Bullish on Aurinia Pharmaceuticals Inc (AUPH) on Back of Attractive Worldwide Partnering Potential in Competitive LN Landscape
- This Bull Sees Meaningful Market Potential for Aurinia Pharmaceuticals Inc (AUPH) Drug Voclosporin in Lupus Nephritis